Targeting angiogenesis in ovarian cancer

Jordan Schmitt, Daniela Matei

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies targeting critical pathways responsible for tumor progression. Angiogenesis is a key process that enables ovarian cancer growth and metastasis in the peritoneal space. Its regulation relies on signaling mechanisms initiated by the vascular endothelial growth factor, the platelet-derived growth factor, the fibroblast growth factor, angiopoietins, and others. These pathways are not only important to the modulation of the tumor microenvironment and vasculature, but also control cancer cell proliferation and survival. In this review, we discuss preclinical evidence supporting the rationale for inhibiting these pathways and provide an overview for the clinical development of agents targeting them. Clinical trials evaluating such agents alone and in combination with chemotherapy are ongoing. Early clinical results position antiangiogenic therapy at the forefront of change to the standard treatment of difficult to treat ovarian cancer.

Original languageEnglish
Pages (from-to)272-283
Number of pages12
JournalCancer Treatment Reviews
Volume38
Issue number4
DOIs
StatePublished - Jun 2012

Fingerprint

Ovarian Neoplasms
Angiopoietins
Critical Pathways
Tumor Microenvironment
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Combination Drug Therapy
Drug Resistance
Vascular Endothelial Growth Factor A
Neoplasms
Cell Survival
Therapeutics
Cell Proliferation
Clinical Trials
Neoplasm Metastasis
Recurrence
Drug Therapy
Growth

Keywords

  • Angiogenesis
  • Angiopoietin
  • Clinical trials
  • FGF
  • Ovarian cancer
  • PDGF
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Targeting angiogenesis in ovarian cancer. / Schmitt, Jordan; Matei, Daniela.

In: Cancer Treatment Reviews, Vol. 38, No. 4, 06.2012, p. 272-283.

Research output: Contribution to journalArticle

Schmitt, Jordan ; Matei, Daniela. / Targeting angiogenesis in ovarian cancer. In: Cancer Treatment Reviews. 2012 ; Vol. 38, No. 4. pp. 272-283.
@article{81694b22b30a4b3c80edd25a52a78e2d,
title = "Targeting angiogenesis in ovarian cancer",
abstract = "Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies targeting critical pathways responsible for tumor progression. Angiogenesis is a key process that enables ovarian cancer growth and metastasis in the peritoneal space. Its regulation relies on signaling mechanisms initiated by the vascular endothelial growth factor, the platelet-derived growth factor, the fibroblast growth factor, angiopoietins, and others. These pathways are not only important to the modulation of the tumor microenvironment and vasculature, but also control cancer cell proliferation and survival. In this review, we discuss preclinical evidence supporting the rationale for inhibiting these pathways and provide an overview for the clinical development of agents targeting them. Clinical trials evaluating such agents alone and in combination with chemotherapy are ongoing. Early clinical results position antiangiogenic therapy at the forefront of change to the standard treatment of difficult to treat ovarian cancer.",
keywords = "Angiogenesis, Angiopoietin, Clinical trials, FGF, Ovarian cancer, PDGF, VEGF",
author = "Jordan Schmitt and Daniela Matei",
year = "2012",
month = "6",
doi = "10.1016/j.ctrv.2011.06.004",
language = "English",
volume = "38",
pages = "272--283",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeting angiogenesis in ovarian cancer

AU - Schmitt, Jordan

AU - Matei, Daniela

PY - 2012/6

Y1 - 2012/6

N2 - Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies targeting critical pathways responsible for tumor progression. Angiogenesis is a key process that enables ovarian cancer growth and metastasis in the peritoneal space. Its regulation relies on signaling mechanisms initiated by the vascular endothelial growth factor, the platelet-derived growth factor, the fibroblast growth factor, angiopoietins, and others. These pathways are not only important to the modulation of the tumor microenvironment and vasculature, but also control cancer cell proliferation and survival. In this review, we discuss preclinical evidence supporting the rationale for inhibiting these pathways and provide an overview for the clinical development of agents targeting them. Clinical trials evaluating such agents alone and in combination with chemotherapy are ongoing. Early clinical results position antiangiogenic therapy at the forefront of change to the standard treatment of difficult to treat ovarian cancer.

AB - Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies targeting critical pathways responsible for tumor progression. Angiogenesis is a key process that enables ovarian cancer growth and metastasis in the peritoneal space. Its regulation relies on signaling mechanisms initiated by the vascular endothelial growth factor, the platelet-derived growth factor, the fibroblast growth factor, angiopoietins, and others. These pathways are not only important to the modulation of the tumor microenvironment and vasculature, but also control cancer cell proliferation and survival. In this review, we discuss preclinical evidence supporting the rationale for inhibiting these pathways and provide an overview for the clinical development of agents targeting them. Clinical trials evaluating such agents alone and in combination with chemotherapy are ongoing. Early clinical results position antiangiogenic therapy at the forefront of change to the standard treatment of difficult to treat ovarian cancer.

KW - Angiogenesis

KW - Angiopoietin

KW - Clinical trials

KW - FGF

KW - Ovarian cancer

KW - PDGF

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84859156536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859156536&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2011.06.004

DO - 10.1016/j.ctrv.2011.06.004

M3 - Article

VL - 38

SP - 272

EP - 283

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 4

ER -